Monthly Archives: December 2017

Top 4 Insurance Stocks To Consider In 2018

Both banking stocks and insurance stocks have done exceptionally well since they literally crashed in 2009. Not only were those sectors hit hardest, they were also suffering from continuously falling interest rates. As interest rates seem to have reached a rock solid bottom, both in the U.S. and recently also in Europe, banking and insurance…

Gold Prices Off Key Support- FOMC Rally Eyes Initial Resistance H

Fundamental Forecast for Gold:Neutral Gold prices respond to critical support; post-FOMC rally under review Gold prices snapped a three-week losing streak with the precious metal up 0.44% to trade at 1253 ahead of the New York close on Friday. The advance comes on the heels of the FOMC policy meeting and amid continued strength risk markets with the all…

As Bitcoin Hits New Highs, Here’s What You Need To Know About The...

Bitcoin is looking like it wants to explode higher again after trading in what counts as a “range” this week. Of course when you’re talking about Bitcoin “rangebound” means something completely different than it does with traditional assets. Specifically, the “range” this week was +/- about $2,000. But jokes aside, it’s broken out on Saturday and…

Australian Dollar May Have Risen As Far As It’s Going This Year

Fundamental Australian Dollar Forecast: Neutral The Australian Dollar got a boost from the general US Dollar weakness engendered by the Fed Then blockbuster local data helped the bulls cause even more This week won’t offer them similar opportunities however The Australian Dollar was borne aloft last week by updrafts foreign and domestic. It was helped by the general US Dollar…

Week In Review: Fosun Signs $125 Million Deal For Ardelyx IBS Tre

Fosun Pharma (SHA: 600196; HK: 2196) obtained China rights to tenapanor, an Ardelyx (Nasdaq: ARDX) treatment for irritable bowel syndrome with constipation (IBS-C), in a $125 million agreement (see story). Tenapanor is also expected to treat hyperphosphatemia related to chronic kidney disease. Ardelyx, a San Francisco area company, has completed US Phase III trials in which tenapanor met efficacy endpoints in both…

“All In” On Tax Reform

  In last week’s “Technically Speaking” post I discussed the S&P 500 hitting 2700 by Christmas. To wit: “As stated in the title, the current push higher puts 2700 in sight by the time Santa fills the ‘stockings hung by the chimney with care.’ As shown below, price momentum triggered a short-term “buy” signal following Thanksgiving, and…

Yield Curve Jitters And Forecasts For The Weeks Of December 18 An

The yield curve is not inverted, and it wouldn’t matter if it were Some people are needlessly worrying about the yield curve inverting and signaling a recession. The economy is showing more vigor — according to the Atlanta Fed model, leading indicators predict a 3.5% fourth-quarter growth. That’s remarkable following second- and third-quarter growth at or above…